CVRX INC
CVRXNASDAQTrading Snapshot
- Day Range
- $2.60 β $2.69
- 52-Week Range
- $2.20 β $11.30
- Volume
- $2.64B
- Avg Volume
- $3.10B
- Shares Outstanding
- 26.5M
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $57M
- Last Q Revenue
- $16M
- P/E Ratio
- -1.3
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-1.96
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +16.0%
Why Investors Own CVRX
- βHigh-growth profile β revenue up +22.1% YoY with expanding US Equity exposure.
- βHealthy economics β 80% gross margin and 11% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CVRX INC
CVRXAbout CVRX INC
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
CVRX INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CVRX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
CVRX INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.